Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Promyelocytic, Acute 1Leukemia 1

Interventions

Tretinoin 10Arsenic Trioxide 10Methotrexate 7Busulfan 7Gemtuzumab 6Cytarabine 6Cyclophosphamide 6Peripheral Blood Stem Cell Transplantation 5Filgrastim 5fludarabine phosphate 4Idarubicin 4Tacrolimus 3Etoposide 3Daunorubicin 3Antilymphocyte Serum 3lintuzumab 2Topotecan 2Radiotherapy 2Mycophenolic Acid 2Mercaptopurine 2Cyclosporins 2Cyclosporine 2Bortezomib 2Azacitidine 2thymoglobulin 1tamibarotene 1sargramostim 1romidepsin 1merphos 1entinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Promyelocytic, Acute × AEG 35156 × Clear all
NCT01018069 2011-07-13

AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen

Aegera Therapeutics

Phase 2 Terminated
60 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Promyelocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡